Targeting the CHI3L1→RAGE→NF-κB axis within astrocytes suppresses maladaptive inflammation and demyelination in NMO while sparing beneficial CHI3L1 functions, offering a precise therapeutic entry point. Here, CHI3L1 is linked to neuromyelitis optica.